AKTX - Akari Therapeutics, Plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.9400
+0.0100 (+0.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.9300
Open1.9200
Bid1.9100 x 3000
Ask1.9400 x 1100
Day's Range1.8800 - 1.9700
52 Week Range1.5600 - 9.2000
Volume175,193
Avg. Volume1,067,021
Market Cap39.593M
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.8740
Earnings DateSep 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.50
Trade prices are not sourced from all markets
  • How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?
    Simply Wall St.

    How Much Cash Is Left In The Bank For Akari Therapeutics, Plc (NASDAQ:AKTX)?

    As the US$39m market cap Akari Therapeutics, Plc (NASDAQ:AKTX) released another year of negative earnings, investors...

  • GlobeNewswire

    Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

    Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression, a growing area of clinical interest. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

    The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

  • GlobeNewswire

    Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).

  • Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
    Zacks

    Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

    Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

  • GlobeNewswire

    Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

    A live audio webcast of the H.C. Wainwright Conference presentation can be accessed by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression, a growing area of clinical interest.

  • Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease
    Zacks

    Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

    The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 30, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Ulta Beauty Inc (NASDAQ: ULTA ) shares were ...

  • Benzinga

    Akari's 2-Day Rally: What You Need To Know

    Akari Therapeutics PLC (NASDAQ: AKTX ) shares are on track to reclaim the $2 level for the first time since mid-August thanks to two doses of positive tidings from the company. Shares of the nanocap biotech ...

  • The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation
    Benzinga

    The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...

  • MarketWatch

    Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan

    Akari Therapeutics PLC shares soared 13% in premarket trade Friday, after the company said it has won U.S. Food and Drug Administration Orphan Drug Designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), a rare disorder. The designation comes after the FDA granted nomacopan Fast Track Designation, which means the regulator will accelerate the approval process. "The granting of orphan drug designation and Fast Track designation by the FDA for nomacopan underscores the significant unmet medical need in this disease," said Clive Richardson, Akari chief executive, in a statement. Shares have gained 22.9% in 2019, while the S&P 500 has gained 16.6%.

  • GlobeNewswire

    Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). Orphan drug designation for nomacopan follows Fast Track designation that the Company received from the FDA earlier in August 2019 for the same indication in pediatric patients.

  • GlobeNewswire

    Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

    - Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemphigoid (BP) announced April 2019Phase.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...

  • Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today
    InvestorPlace

    Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today

    Some recent biopharma news concerning Akari Therapeutics has AKTX stock flying high on Wednesday.Source: Shutterstock The biopharma news has to do with Akari Therapeutics (NASDAQ:AKTX) getting Fast Track designation from the U.S. Food & Drug Administration (FDA) for one of its treatments. This allows the company to speed up testing of the drug. The designation is typically given to medicine with potential to treat illnesses that don't already have wide coverage.The Fast Track designation from the FDA is for Akari Therapeutics' nomacopan. This is the company's drug for treating HSCT-TMA. HSCT-TMA is an orphan condition with an estimated fatality rate of more than 80% in children that suffer from it. There currently isn't an approved treatment for this illness.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe positive biopharma news for AKTX stock comes after the successful treating of two patients in the U.S. with nomacopan. With these results and the FDA's approval, the company is now planning to launch a clinical trial of the treatment in the fourth quarter of 2019. * 15 Growth Stocks to Buy for the Long Haul "We see HSCT-TMA as a gateway into a range of other poorly treated orphan TMAs in both pediatric and adult patients, and are optimistic about the potential for nomacopan to offer an improved standard of care for these orphan conditions with high mortality rates," Clive Richardson, interim CEO of Akari Therapeutics, said in a statement.AKTX stock was up 32% as of Wednesday morning and is up 7% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 As of this writing, William White did not hold a position in any of the aforementioned securities.The post Biopharma News: Why Akari Therapeutics (AKTX) Stock Is Soaring Today appeared first on InvestorPlace.

  • MarketWatch

    Akari Therapeutics' stock rockets on heavy volume after FDA grants nomacopan 'Fast Track' designation

    Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients was granted "Fast Track" designation by the U.S. Food and Drug Administration. Trading volume swelled to 1.7 million shares, compared with the full-day average of about 96,000 shares. A Fast Track designation helps facilitate the development and expedite the review of new drugs for the treatment of serious or life-threatening conditions that address unmet medical needs. ""Fast Track designation provides our HSCT-TMA clinical program a pathway for an expedited approval for nomacopan, and we plan to commence a pivotal trial in the fourth quarter of 2019," said Chief Executive Clive Richardson. The stock has tumbled 42% over the past three months, while the iShares Nasdaq Biotechnology ETF has gained 2.9% and the S&P 500 has tacked on 3.2%.

  • GlobeNewswire

    Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

    Fast Track designation by the U.S. Food and Drug Administration (FDA) facilitates the development and expedites the review of new medicines like nomacopan that treat serious unmet medical needs and in Akari’s case, pediatric patients with HSCT-TMA. The Fast Track designation follows a successful pre-investigational new drug (IND) FDA meeting earlier this year regarding Akari’s proposed pivotal clinical trial program for HSCT-TMA. The FDA is working with Akari in its optimization of pediatric dosing for HSCT-TMA by Akari’s participation in the FDA Model-Informed Drug Development (MIDD) Program with supportive PK data provided by pediatric patients already treated with nomacopan as part of a named patient program.

  • GlobeNewswire

    Akari Therapeutics announces new data demonstrating synergistic benefits of nomacopan’s bifunctional C5 and LTB4 inhibitory activity in pemphigoid disease

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced new preclinical and human data demonstrating the potential benefits of the dual inhibition of complement (C5) and leukotriene (LTB4) pathways by nomacopan for the treatment of pemphigoid disease (PD).

  • GlobeNewswire

    Akari Therapeutics Announces Oral Presentation of Nomacopan Phase II Data in Patients with Bullous Pemphigoid at the 28th European Academy of Dermatology and Venereology (EADV) Congress, October 9-13, 2019

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced an oral presentation will be given at the 28th EADV Congress. The oral presentation will describe the safety and efficacy data from Akari’s Phase II clinical trial of nomacopan in adult patients with mild to moderate bullous pemphigoid.

  • Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Akari Therapeutics, Plc (NASDAQ:AKTX), Consider Its Volatility

    Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share...

  • Alexion's Ultomiris Receives EU Approval for PNH in Adults
    Zacks

    Alexion's Ultomiris Receives EU Approval for PNH in Adults

    Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.

  • GlobeNewswire

    Akari Therapeutics, Plc Announces $4.5 Million Registered Direct Offering

    Akari Therapeutics, Plc (AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced that it has entered into definitive agreements with certain institutional investors, accredited investors and an existing shareholder, RPC Pharma Ltd., an affiliated entity of Dr. Ray Prudo, Akari’s Chairman, to receive gross proceeds of $4.5 million. In connection with the offering, the Company will issue approximately 2,368,421 registered American Depository Shares (ADSs) of Akari at a purchase price of $1.90 per ADS in a registered direct offering.

  • Alexion Receives FDA Approval for Label Expansion of Soliris
    Zacks

    Alexion Receives FDA Approval for Label Expansion of Soliris

    Alexion (ALXN) obtains FDA approval for Soliris for the treatment of neuromyelitis optica spectrum disorder.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
    Zacks

    Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

    Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.